AstraZeneca reported better-than-expected Q2 earnings, with core EPS of $2.63 and revenue of $15.38 billion, up about 5% year over year at constant currency, driven by a 15% rise in oncology sales. The company highlighted strong performances from Imfinzi, Calquence, Tagrisso and Enhertu, and reiterated mid-to-high single-digit revenue growth and low-double-digit core EPS growth guidance for 2026, while pursuing an ambitious $80 billion annual revenue target for 2030. CEO Pascal Soriot emphasized confidence in the pipeline, noting more than twenty high-value readouts over the next 18 months. AstraZeneca warned of mixed near-term trajectory due to recent clinical setbacks, including trials of Wainua and Ultomiris that missed targets, though a gastric cancer trial showed positive results. China remains a pressure point with revenue decline due to generic competition and policy shifts, while the US and other markets contributed to overall growth. The firm continues to invest in transformative technologies and commercial execution as it pursues its long-term growth plan.